RxDoctor Payments Data

Monica Johnson, APRN

Family · Mt Sterling, KYNPI 1861990228

Payments from drug & device makers

$1,692in general payments, 2019–2025

Across 90 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • GSK$172
  • AstraZeneca$89
  • Otsuka America Pharmaceutical, Inc.$68
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
  • Indivior Inc.$55
  • plus $544 from 21 others

What the payments were for

  • Food & beverage$1,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,692 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$337
Medicare patients
14
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$89,443
JardianceEmpagliflozin72$66,710
JanuviaSitagliptin Phosphate61$53,045
OzempicSemaglutide40$42,042
EliquisApixaban36$42,037
FarxigaDapagliflozin Propanediol42$38,655
TradjentaLinagliptin18$16,646
Spiriva RespimatTiotropium Bromide20$16,457
LinzessLinaclotide15$14,862
TrulicityDulaglutide12$11,401
Breo ElliptaFluticasone/Vilanterol14$7,939
SymbicortBudesonide/Formoterol Fumarate23$7,436
Albuterol Sulfate HfaAlbuterol Sulfate201$5,853
Novolog FlexpenInsulin Aspart24$4,700
Levemir FlexpenInsulin Detemir11$3,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$13$99,813110 claims
GSKTrelegy Ellipta, Breo Ellipta$172$97,381136 claims
MerckJanuvia$14$53,04561 claims
AstraZenecaFarxiga, Symbicort$89$46,09165 claims
Novo NordiskOzempic$35$42,04240 claims
PfizerEliquis$15$42,03736 claims
AbbVieLinzess, Synthroid$702$15,48331 claims
Lilly USA, LLCTrulicity$13$11,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Mt Sterling

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →